ERBB2 and breast cancer: Therefore, patients with breast cancers that overexpress HER2, which constitute about 10–30% of all breast cancers [116], could perhaps benefit from this treatment in the future; however, its more harmful effects on normal mammary epithelial cells need to be considered.